Health
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease – nejm.org
Original Article from The New England Journal of Medicine — Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
From the DanaFarber/Boston Childrens Cancer and Blood Disorders Center, Harvard Medical School (E.B.E., L.E.L., A.B., C.B., M.F.C., B.M., K.B., S.-Y.P., W.B.L., C.D., M.M.H., D.A.W.), the Harvard Stem Cell Institute, Harvard Medical School (A.B., C.B.), the Gene Therapy Program, DanaFarber/Boston Childrens Cancer and Blood Disorders Center (A.B., M.F.C., B.M., E.M., A.F., S.-Y.P., C.D., D.A.W.), the Division of Hematology, Brigham and Womens Hospital, Harvard Medical School (M. Achebe), the Connell…
-
General13 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General15 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News15 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business12 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher